Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer
NCT ID: NCT03768570
Last Updated: 2026-02-02
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
ACTIVE_NOT_RECRUITING
Clinical Phase
PHASE2
Total Enrollment
82 participants
Study Classification
INTERVENTIONAL
Study Start Date
2019-10-25
Study Completion Date
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to find out what effects durvalumab has on bladder cancer, combined with treatment after completion of surgery, chemotherapy and radiotherapy.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach
NCT03702179
Invasive Bladder Cancer
COMPLETED
PHASE2
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
NCT03732677
Muscle Invasive Bladder Cancer
ACTIVE_NOT_RECRUITING
PHASE3
TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder Cancer
NCT04073160
Bladder Cancer
WITHDRAWN
PHASE1
Trimodality Treatment in Bladder Cancer
NCT06395701
Bladder Cancer
Urinary Bladder Neoplasms
Bladder Disease
COMPLETED
Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)
NCT03472274
Bladder Cancer
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study is looking at whether a type of immunotherapy drug called durvalumab can be safely administered after initial treatment received by a patient. Durvalumab has been tested in many different types of cancers. Durvalumab works by allowing the immune system to detect cancer and reactivate the immune response. This may help to slow down the growth of cancer or may cause cancer cells to die. It is unclear if the addition of durvalumab is beneficial in patients with bladder cancer who have completed surgery, radiotherapy and chemotherapy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Bladder Cancer
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Surveillance
Group Type
NO_INTERVENTION
No interventions assigned to this group
Durvalumab
Group Type
ACTIVE_COMPARATOR
Durvalumab
Intervention Type
DRUG
1500 mg IV on day 1 of 4 week cycle every 4 weeks for 12 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Durvalumab
1500 mg IV on day 1 of 4 week cycle every 4 weeks for 12 months
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologic diagnosis of urothelial carcinoma of the bladder. Patients with mixed histology (including small cell) and urothelial carcinoma are eligible. Patients with pure small cell carcinoma will be excluded.
* Stage T2-T4a N0M0 at time of diagnosis based on trans-urethral resection of bladder tumour, imaging, and/or bimanual examination under anesthesia.
* CT scan of the chest/abdomen/pelvis within 8 weeks from enrollment, showing no evidence of metastatic disease.
* Patients must be ≥ 18 years of age.
* Patients must have a life expectancy greater than 6 months.
* Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 and a body weight of \> 30kg.
* Patients must have adequate hematologic reserve: Platelet count ≥ 75 x 10\^9/L, Absolute neutrophils ≥ 1.0 x 10\^9/L. Anemia will be corrected to minimum hemoglobin of 90 g/L with red cell transfusions, if necessary.
* Patients must have an estimated creatinine clearance (Cockcroft-Gault Equation) ≥ 30 ml/min.
* Patients must have adequate liver function with a bilirubin ≤ 1.5 ULN (if confirmed Gilbert's, eligible providing bilirubin ≤ 3 x UNL) and AST/ALT (SGOT/SGPT) \< 2.5 x the upper normal limit.
* All patients must have a tumour block from their primary tumour available and consent to release the block/cores/cut slides for correlative analyses ( and the centre/pathologist must have agreed to the submission of the specimen(s).
* Patients have completed prior trimodality therapy (TMT) consisting of surgery, chemotherapy and radiation therapy treatment prior to enrollment. Patient should start treatment within 42 days after completion of TMT.
* Patients must have undergone a transurethral resection prior to study enrollment.
* Patient may have completed up to 4 cycles of cisplatin-based neo-adjuvant chemotherapy. Adjuvant chemotherapy is not permitted. Patients will have received cisplatin, given intravenously during the radiation therapy. OR Patients may have received fluorouracil and mitomycin given intravenously once weekly or gemcitabine as an alternative to cisplatin during radiotherapy.
* The following are radiotherapy guidelines for patients treated on study. Patients will be treated to radical treatment doses using IMRT, VMAT or 4 field conformal techniques. Planning will be based on CT planning. IGRT is recommended during the radiotherapy treatment. Recognizing differences in usual radiotherapy doses used in the various participating countries and centres the following would be acceptable doses in this study. The bladder CTV will include the whole empty bladder and any extravesical extension. PTV expansion will be a minimum of 0.75 cm right, left and inferiorly, 1.5 cm Anteriorly and superiorly and 1 cm posteriorly. These minimum expansions are with Cone beam verification. For patients undergoing RT without image-guided verification 1.5 cm expansion in all directions is recommended. Acceptable doses for this study include:
* Bladder only: 64-66 Gy in 32-33 fractions over 6.5 weeks; 50-55 Gy in 20 fractions over 4 weeks
* Pelvis and bladder: 45-46 Gy to pelvic nodes + 17-20 Gy bladder boost in 33-35 fractions over 6.5-7 wks \[Note: minimal nodal dose (if used) is 44 Gy in 32f or 40 Gy in 20f\]
* Patients receiving concurrent bladder boost: pelvis dose 40 Gy and bladder dose 50 Gy given in 20 fractions over 4 weeks. Adaptive radiotherapy techniques would be acceptable.
* Patient is able (i.e. sufficiently fluent) and willing to complete the quality of life questionnaires in either English, French or Spanish.
* Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate.
* Patients must be accessible for treatment and follow up. Patients registered on this trial must be treated and followed at the participating centre. This implies there must be reasonable geographical limits placed on patients being considered for this trial.
* In accordance with CCTG policy, protocol treatment is to begin within 2 working days of patient enrollment.
* Women/men of childbearing potential must have agreed to use a highly effective contraceptive method during and for 3 months following treatment.
* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
* Stage T2-T4a N0M0 at time of diagnosis based on trans-urethral resection of bladder tumour, imaging, and/or bimanual examination under anesthesia.
* CT scan of the chest/abdomen/pelvis within 8 weeks from enrollment, showing no evidence of metastatic disease.
* Patients must be ≥ 18 years of age.
* Patients must have a life expectancy greater than 6 months.
* Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 and a body weight of \> 30kg.
* Patients must have adequate hematologic reserve: Platelet count ≥ 75 x 10\^9/L, Absolute neutrophils ≥ 1.0 x 10\^9/L. Anemia will be corrected to minimum hemoglobin of 90 g/L with red cell transfusions, if necessary.
* Patients must have an estimated creatinine clearance (Cockcroft-Gault Equation) ≥ 30 ml/min.
* Patients must have adequate liver function with a bilirubin ≤ 1.5 ULN (if confirmed Gilbert's, eligible providing bilirubin ≤ 3 x UNL) and AST/ALT (SGOT/SGPT) \< 2.5 x the upper normal limit.
* All patients must have a tumour block from their primary tumour available and consent to release the block/cores/cut slides for correlative analyses ( and the centre/pathologist must have agreed to the submission of the specimen(s).
* Patients have completed prior trimodality therapy (TMT) consisting of surgery, chemotherapy and radiation therapy treatment prior to enrollment. Patient should start treatment within 42 days after completion of TMT.
* Patients must have undergone a transurethral resection prior to study enrollment.
* Patient may have completed up to 4 cycles of cisplatin-based neo-adjuvant chemotherapy. Adjuvant chemotherapy is not permitted. Patients will have received cisplatin, given intravenously during the radiation therapy. OR Patients may have received fluorouracil and mitomycin given intravenously once weekly or gemcitabine as an alternative to cisplatin during radiotherapy.
* The following are radiotherapy guidelines for patients treated on study. Patients will be treated to radical treatment doses using IMRT, VMAT or 4 field conformal techniques. Planning will be based on CT planning. IGRT is recommended during the radiotherapy treatment. Recognizing differences in usual radiotherapy doses used in the various participating countries and centres the following would be acceptable doses in this study. The bladder CTV will include the whole empty bladder and any extravesical extension. PTV expansion will be a minimum of 0.75 cm right, left and inferiorly, 1.5 cm Anteriorly and superiorly and 1 cm posteriorly. These minimum expansions are with Cone beam verification. For patients undergoing RT without image-guided verification 1.5 cm expansion in all directions is recommended. Acceptable doses for this study include:
* Bladder only: 64-66 Gy in 32-33 fractions over 6.5 weeks; 50-55 Gy in 20 fractions over 4 weeks
* Pelvis and bladder: 45-46 Gy to pelvic nodes + 17-20 Gy bladder boost in 33-35 fractions over 6.5-7 wks \[Note: minimal nodal dose (if used) is 44 Gy in 32f or 40 Gy in 20f\]
* Patients receiving concurrent bladder boost: pelvis dose 40 Gy and bladder dose 50 Gy given in 20 fractions over 4 weeks. Adaptive radiotherapy techniques would be acceptable.
* Patient is able (i.e. sufficiently fluent) and willing to complete the quality of life questionnaires in either English, French or Spanish.
* Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate.
* Patients must be accessible for treatment and follow up. Patients registered on this trial must be treated and followed at the participating centre. This implies there must be reasonable geographical limits placed on patients being considered for this trial.
* In accordance with CCTG policy, protocol treatment is to begin within 2 working days of patient enrollment.
* Women/men of childbearing potential must have agreed to use a highly effective contraceptive method during and for 3 months following treatment.
* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
Exclusion Criteria
* Pre-existing medical conditions precluding treatment.
* Pregnancy or lactating mothers.
* Received prior therapy with an anti-programmed cell death protein 1 (anti-PD-1), anti-PD-L1, including durvalumab anti-programmed cell death-ligand 2 (anti-PD-L2), anti-CD137 (4-1BB ligand, a member of the Tumour Necrosis Factor Receptor \[TNFR\] family), or anti-Cytotoxic T-lymphocyte-associated antigen-4 (anti-CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).
* Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease (e.g. colitis or Crohn's disease: not due to radiation reaction), diverticulitis with the exception of diverticulosis, celiac disease (controlled by diet alone) or other serious gastrointestinal chronic conditions associated with diarrhea), systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome (granulomatosis with polyangiitis), rheumatoid arthritis, hypophysitis, uveitis, etc., within the past 3 years prior to the start of treatment. The following are exceptions to this criterion:
* Patients with alopecia;
* Patients with Grave's disease, vitiligo or psoriasis not requiring systemic treatment (within the last 2 years);
* Patients with hypothyroidism (e.g. following Hashimoto syndrome) stable on hormone replacement;
* Any chronic skin condition that does not require systemic therapy.
* Patients with active or uncontrolled intercurrent illness including, but not limited to:
* cardiac dysfunction (symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia);
* active peptic ulcer disease or gastritis;
* active bleeding diatheses;
* psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent;
* known history of previous clinical diagnosis of tuberculosis;
* known active human immunodeficiency virus infection (positive HIV 1/2 antibodies). HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible;
* known active hepatitis B infection (positive HBV surface antigen (HBsAg). Patients with a past or resolved HBV infection (defined as presence of hepatitis B core antibody (anti-HBc) and absence of HBsAg) are eligible;
* known active hepatitis C infection. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
* History of primary immunodeficiency, history of allogenic organ transplant that requires therapeutic immunosuppression and the use of immunosuppressive agents within 28 days of randomization or a prior history of severe (grade 3 or 4) immune mediated toxicity from other immune therapy or grade ≥ 3 infusion reaction.
* Current or prior use of immunosuppressive medication within 28 days of study entry, with the exceptions of intranasal and inhaled corticosteroids or systemic chronic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid. Corticosteroids used on study for anti-emetic purpose are allowed. Corticosteroids as premedication for hypersensitivity reactions (e.g. computed tomography \[CT\] scan premedication) are allowed.
* Peripheral neuropathy ≥ grade 2 (CTCAE v5.0).
* History of allergic or hypersensitivity reactions to any study drug or their excipients.
* Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 msec in screening ECG measured using standard institutional method or history of familial long QT syndrome.
* History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline CT scan.
* Any active disease condition which would render the protocol treatment dangerous or impair the ability of the patient to receive protocol therapy.
* Any condition (e.g. psychological, geographical, etc.) that does not permit compliance with the protocol.
* Live attenuated vaccination administered within 30 days prior to randomization.
* Any prior carboplatin based therapy.
* Pregnancy or lactating mothers.
* Received prior therapy with an anti-programmed cell death protein 1 (anti-PD-1), anti-PD-L1, including durvalumab anti-programmed cell death-ligand 2 (anti-PD-L2), anti-CD137 (4-1BB ligand, a member of the Tumour Necrosis Factor Receptor \[TNFR\] family), or anti-Cytotoxic T-lymphocyte-associated antigen-4 (anti-CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).
* Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease (e.g. colitis or Crohn's disease: not due to radiation reaction), diverticulitis with the exception of diverticulosis, celiac disease (controlled by diet alone) or other serious gastrointestinal chronic conditions associated with diarrhea), systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome (granulomatosis with polyangiitis), rheumatoid arthritis, hypophysitis, uveitis, etc., within the past 3 years prior to the start of treatment. The following are exceptions to this criterion:
* Patients with alopecia;
* Patients with Grave's disease, vitiligo or psoriasis not requiring systemic treatment (within the last 2 years);
* Patients with hypothyroidism (e.g. following Hashimoto syndrome) stable on hormone replacement;
* Any chronic skin condition that does not require systemic therapy.
* Patients with active or uncontrolled intercurrent illness including, but not limited to:
* cardiac dysfunction (symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia);
* active peptic ulcer disease or gastritis;
* active bleeding diatheses;
* psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent;
* known history of previous clinical diagnosis of tuberculosis;
* known active human immunodeficiency virus infection (positive HIV 1/2 antibodies). HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible;
* known active hepatitis B infection (positive HBV surface antigen (HBsAg). Patients with a past or resolved HBV infection (defined as presence of hepatitis B core antibody (anti-HBc) and absence of HBsAg) are eligible;
* known active hepatitis C infection. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
* History of primary immunodeficiency, history of allogenic organ transplant that requires therapeutic immunosuppression and the use of immunosuppressive agents within 28 days of randomization or a prior history of severe (grade 3 or 4) immune mediated toxicity from other immune therapy or grade ≥ 3 infusion reaction.
* Current or prior use of immunosuppressive medication within 28 days of study entry, with the exceptions of intranasal and inhaled corticosteroids or systemic chronic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid. Corticosteroids used on study for anti-emetic purpose are allowed. Corticosteroids as premedication for hypersensitivity reactions (e.g. computed tomography \[CT\] scan premedication) are allowed.
* Peripheral neuropathy ≥ grade 2 (CTCAE v5.0).
* History of allergic or hypersensitivity reactions to any study drug or their excipients.
* Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 msec in screening ECG measured using standard institutional method or history of familial long QT syndrome.
* History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline CT scan.
* Any active disease condition which would render the protocol treatment dangerous or impair the ability of the patient to receive protocol therapy.
* Any condition (e.g. psychological, geographical, etc.) that does not permit compliance with the protocol.
* Live attenuated vaccination administered within 30 days prior to randomization.
* Any prior carboplatin based therapy.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Sponsor Role
collaborator
Canadian Cancer Trials Group
NETWORK
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wassim Kassouf
Role: STUDY_CHAIR
The Research Institute of the McGill University, Montreal QC Canada
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tom Baker Cancer Centre
Calgary, Alberta, Canada
Site Status
Cross Cancer Institute
Edmonton, Alberta, Canada
Site Status
BCCA - Vancouver Cancer Centre
Vancouver, British Columbia, Canada
Site Status
Health Sciences North
Greater Sudbury, Ontario, Canada
Site Status
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, Canada
Site Status
Kingston Health Sciences Centre
Kingston, Ontario, Canada
Site Status
London Regional Cancer Program
London, Ontario, Canada
Site Status
Stronach Regional Health Centre at Southlake
Newmarket, Ontario, Canada
Site Status
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
Site Status
Thunder Bay Regional Health Sciences Centre/
Thunder Bay, Ontario, Canada
Site Status
University Health Network
Toronto, Ontario, Canada
Site Status
The Jewish General Hospital
Montreal, Quebec, Canada
Site Status
The Research Institute of the McGill University
Montreal, Quebec, Canada
Site Status
Allan Blair Cancer Centre
Regina, Saskatchewan, Canada
Site Status
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, Canada
Site Status
Hospital Clinic i Provincial
Barcelona, , Spain
Site Status
Hospital de la Santa Creu i Sant Pau
Barcelona, , Spain
Site Status
Hospital Clinico San Carlos
Madrid, , Spain
Site Status
Hospital 12 de Octubre
Madrid, , Spain
Site Status
Hospital Universitario La Paz
Madrid, , Spain
Site Status
Hospital Madrid Norte Sanchinarro
Madrid, , Spain
Site Status
Hospital Universitario Marques de Valdecilla
Santander, , Spain
Site Status
Instituto Valenciano de Oncologia
Valencia, , Spain
Site Status
Royal Devon and Exeter Hospital
Exeter, Devon, United Kingdom
Site Status
Royal Cornwall Hospitals NHS Trust
Cornwall, England, United Kingdom
Site Status
Royal Preston Hospital
Lancashire, England, United Kingdom
Site Status
Charing Cross Hospital
London, England, United Kingdom
Site Status
The Christie NHS Foundation Trust
Manchester, England, United Kingdom
Site Status
The Royal Marsden NHS Foundation Trust - Sutton
Surrey, England, United Kingdom
Site Status
University Hospital Southampton NHS Foundation Trust
Southampton, Hampshire, United Kingdom
Site Status
Nottingham University Hospitals City Hospital Campus
Nottingham, , United Kingdom
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Canada
Spain
United Kingdom
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019-001310-42
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
BL13
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer
NCT03601455
ACTIVE_NOT_RECRUITING
PHASE2
Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer
NCT05120622
WITHDRAWN
PHASE1/PHASE2
Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer
NCT03620435
UNKNOWN
PHASE2
Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy
NCT04579133
TERMINATED
PHASE2
Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder
NCT02891161
TERMINATED
PHASE1/PHASE2
A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
NCT06503614
RECRUITING
PHASE2
Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer
NCT04289779
ACTIVE_NOT_RECRUITING
PHASE2
NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma
NCT03549715
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
NCT03317158
RECRUITING
PHASE1/PHASE2
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
NCT04960709
ACTIVE_NOT_RECRUITING
PHASE3
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)
NCT02951767
COMPLETED
PHASE2
Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin
NCT03234153
TERMINATED
PHASE2
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
NCT04628767
RECRUITING
PHASE2/PHASE3
Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy
NCT03697850
ACTIVE_NOT_RECRUITING
PHASE2
Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer
NCT03528694
ACTIVE_NOT_RECRUITING
PHASE3
Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer
NCT03473730
COMPLETED
EARLY_PHASE1
A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial
NCT04216290
ACTIVE_NOT_RECRUITING
PHASE2
Sequential Combination Therapy in Bladder Cancer
NCT03790384
UNKNOWN
PHASE4
Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery
NCT02812420
ACTIVE_NOT_RECRUITING
EARLY_PHASE1
Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma
NCT04701918
COMPLETED
PHASE2
A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder
NCT05137262
RECRUITING
PHASE2
Chemotherapy in Treating Patients With Early-Stage Bladder Cancer
NCT00003129
COMPLETED
PHASE2
Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC
NCT04543110
UNKNOWN
PHASE2
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
NCT03775265
ACTIVE_NOT_RECRUITING
PHASE3
Combination Chemotherapy in Treating Patients With Bladder Cancer
NCT00003701
COMPLETED
PHASE3